Intensity Therapeutics grants CFO 34,000 options

Intensity Therapeutics granted its Chief Financial Officer, Joseph Talamo, a stock option for 34,000 shares of Common Stock on July 16, 2026.

Accepted by SEC EDGAR 07/20/2026 - 04:02 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Intensity Therapeutics granted its Chief Financial Officer, Joseph Talamo, a stock option for 34,000 shares of Common Stock on July 16, 2026. The option has a $4.90 per-share exercise price and expires on July 16, 2036.

According to the terms, the option will vest in four equal annual installments beginning July 16, 2027, conditioned on his continued service with the company. Following this grant, Talamo holds 34,000 stock options directly.

Insider Trade Summary

Grant/Award: 34,000 shares

Grant/Award 1 txn

Insider Talamo Joseph

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy Common Stock) F1	34,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy Common Stock) — 34,000 contracts (Direct)

Holdings Before and After: Stock Option (right to buy Common Stock), 0 to 34,000 contracts (Direct)

Footnotes (1)

1. F1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2027.

Key Figures

Stock options granted: 34,000 shares Exercise price: $4.90 per share Shares underlying option: 34,000 shares +2 more

5 metrics

Stock options granted 34,000 shares Grant of Stock Option to CFO on July 16, 2026

Exercise price $4.90 per share Conversion or exercise price of the Stock Option

Shares underlying option 34,000 shares Common Stock underlying the Stock Option grant

Vesting schedule 4 annual installments Option vests in four equal annual installments beginning July 16, 2027

Expiration date July 16, 2036 Option expiration stated for the Stock Option grant

Key Terms

Stock Option (right to buy Common Stock), conversion or exercise price, vesting

3 terms

Stock Option (right to buy Common Stock) financial

"security_title: Stock Option (right to buy Common Stock)"

conversion or exercise price financial

"conversion_or_exercise_price: 4.9000"

vesting financial

"This option will vest, subject to the individual's continued service"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Intensity Therapeutics (INTS) report for CFO Joseph Talamo?

Intensity Therapeutics reported that CFO Joseph Talamo received a grant of 34,000 stock options for Common Stock. These options have a $4.90 exercise price per share and represent a compensation-related award rather than an open-market purchase or sale of existing shares.

How many Intensity Therapeutics (INTS) options did the CFO receive and at what exercise price?

CFO Joseph Talamo received 34,000 stock options linked to Intensity Therapeutics Common Stock. The options carry a $4.90 per-share exercise price, meaning he can purchase shares at that price once the options have vested and are exercised before expiration.

When do Joseph Talamo’s Intensity Therapeutics (INTS) stock options vest?

The stock options granted to CFO Joseph Talamo will vest in four equal annual installments starting on July 16, 2027. Vesting is explicitly conditioned on his continued service with Intensity Therapeutics, so remaining employed is required to receive each installment.

When do the CFO’s Intensity Therapeutics (INTS) stock options expire?

The granted stock options are scheduled to expire on July 16, 2036. Talamo may exercise vested options at the $4.90 per-share price any time after vesting and before that expiration date, subject to the company’s applicable equity plan terms and policies.

Were the Intensity Therapeutics (INTS) CFO option grants made under a Rule 10b5-1 trading plan?

The filing shows the Rule 10b5-1 checkbox was not marked, so the transaction was not reported as made under a Rule 10b5-1 trading plan. It is disclosed as a standard equity compensation grant rather than as part of a pre-arranged trading program.

How many Intensity Therapeutics (INTS) derivative securities does the CFO hold after this grant?

Following this award, CFO Joseph Talamo is reported as directly holding 34,000 stock options related to Intensity Therapeutics Common Stock. This figure reflects the total derivative securities from this specific grant as of the reported transaction date in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Talamo Joseph

(Last) (First) (Middle)

C/O INTENSITY THERAPEUTICS, INC.

1 ENTERPRISE DRIVE, SUITE 430

(Street)

SHELTON CONNECTICUT 06484

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTENSITY THERAPEUTICS, INC. [ INTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy Common Stock)	$4.9	07/16/2026		A		34,000		07/16/2027(1)	07/16/2036	Common Stock	34,000	$0	34,000	D

Explanation of Responses:

1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2027.

Remarks:

	/s/ Joseph Talamo	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)